These findings highlight the potential utility of LCN2, ELANE, CAMP, and CTSG as biomarkers for assessing neurological disability in MS, with LTF providing additional, albeit more moderate, predictive value. This evidence concerns the gene LCN2 and myeloid sarcoma.